Lupus & antiphospholipid syndrome
Steroid-induced diabetes in lupus nephritis patients: Classic risk factors or a different type of diabetes?
Authors' conclusion
In conclusion, SDI development in patients receiving induction therapy for LN is associated with both classic metabolic risk factors and SLE-specific factors, and antimalarial use could be associated with a protective effect.
Study context
- Population
- Patients with biopsy-proven lupus nephritis (LN) who received induction treatment with steroids35 (9.7%) developed steroid-induced diabetes (SID)
- Participants
- 358 patients
- Comparison
- LN patients who developed SID vs those who did not
- SIDn = 35
- Outcome
- Risk factors associated with the development of SID
Methodological detailslogistic regression, propensity score matching
- Logistic regression
- Propensity score matching
Main finding
As reported in the abstract
Variables associated with SID development (logistic regression)
Odds ratio (95% CI)P value
SLEDAI index
1.25(1.04–1.50)
p 0.01SLICC-DI
4.93(2.14–11.3)
P < 0.001METS-IR
1.17(1.04–1.32)
p 0.009Delta METS-IR at 6 months
1.20(1.03–1.39)
p 0.01Antimalarial use
0.14(0.02–0.85)
p 0.03Observational data: associations, not effects.
Further findings
Metabolic score for insulin resistance (METS-IR) >36.8 and SID risk (after propensity score matching)
| OR (95% CI) | P value | ||
|---|---|---|---|
| METS-IR >36.8 | 2.83 (1.09–7.36) | P = 0.034 | |
| 0.10.31310Odds ratio (log scale) |
- After propensity score matching, METS-IR remained a significant predictor of SID
Original publication
Steroid-induced diabetes in lupus nephritis patients: Classic risk factors or a different type of diabetes? Lupus. Published 22 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →